In the early days of the pandemic, researchers raced to establish the most potent antibodies produced by the immune system in response to SAR-COV-2 an infection and produce them in bulk. The ensuing ‘monoclonal antibodies’ have since been examined in quite a lot of settings as treatments for COVID-19.
But regardless of promising medical trial outcomes and several other therapies having already been authorised, antibody therapies have not but performed a big position in the battle towards COVID-19. In this episode of Coronapod, we ask why.
News: COVID antibody treatments show promise for preventing severe disease News: Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?
Never miss an episode: Subscribe to the Nature Podcast on Apple Podcasts, Google Podcasts, Spotify or your favorite podcast app. Head right here for the Nature Podcast RSS feed.
